Melanoma - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Melanoma - Pipeline Review, H2 2018’, provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Melanoma

- The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects

- The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Melanoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced BioDesign

Advenchen Laboratories LLC ...

4D Pharma PLC

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced BioDesign

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Afecta Pharmaceuticals Inc

Affichem SA

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

AiVita Biomedical Inc

Alkermes Plc

Allergy Therapeutics Plc

Alligator Bioscience AB

Altor BioScience Corp

Amgen Inc

Angimmune LLC

Antibe Therapeutics Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Aprea AB

Aptose Biosciences Inc

Arcus Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascentage Pharma Group Corp Ltd

Astex Pharmaceuticals Inc

Atreca Inc

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Autolus Therapeutics Plc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Biocad

Bio-Cancer Treatment International Ltd

Biogazelle NV

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioLineRx Ltd

Bionomics Ltd

BioNTech AG

Biosion Inc

Biothera Pharmaceutical Inc

BioVaxys LLC

Biovista Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Can-Fite BioPharma Ltd

CBT Pharmaceuticals Inc

Celdara Medical LLC

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celprogen Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Constellation Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cue Biopharma Inc

Curevac AG

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytoVac AS

CyTuVax BV

CZ BioMed Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DNAtrix Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Co

Elsalys Biotech SA

Emcure Pharmaceuticals Ltd

EntreChem SL

eTheRNA Immunotherapies NV

Evelo Biosciences Inc

Evotec AG

Exelixis Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 12

Melanoma - Overview 13

Melanoma - Therapeutics Development 14

Melanoma - Therapeutics Assessment 80

Melanoma - Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 12

Melanoma - Overview 13

Melanoma - Therapeutics Development 14

Melanoma - Therapeutics Assessment 80

Melanoma - Companies Involved in Therapeutics Development 114

Melanoma - Drug Profiles 240

Melanoma - Dormant Projects 2161

Melanoma - Discontinued Products 2195

Melanoma - Product Development Milestones 2200

Appendix 2213

List of Tables

List of Tables

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 87

Number of ...

List of Tables

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 87

Number of Products under Development by Universities/Institutes, H2 2018 108

Products under Development by Companies, H2 2018 113

Products under Development by Universities/Institutes, H2 2018 144

Number of Products by Stage and Target, H2 2018 152

Number of Products by Stage and Mechanism of Action, H2 2018 167

Number of Products by Stage and Route of Administration, H2 2018 182

Number of Products by Stage and Molecule Type, H2 2018 184

Melanoma - Pipeline by 4D Pharma PLC, H2 2018 185

Melanoma - Pipeline by 4P-Pharma SAS, H2 2018 185

Melanoma - Pipeline by 4SC AG, H2 2018 186

Melanoma - Pipeline by AB Science SA, H2 2018 186

Melanoma - Pipeline by AbbVie Inc, H2 2018 187

Melanoma - Pipeline by Abivax SA, H2 2018 187

Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2018 188

Melanoma - Pipeline by Aduro BioTech Inc, H2 2018 188

Melanoma - Pipeline by Advanced BioDesign, H2 2018 189

Melanoma - Pipeline by Advenchen Laboratories LLC, H2 2018 189

Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2018 190

Melanoma - Pipeline by Afecta Pharmaceuticals Inc, H2 2018 190

Melanoma - Pipeline by Affichem SA, H2 2018 190

Melanoma - Pipeline by Agenus Inc, H2 2018 191

Melanoma - Pipeline by AGV Discovery SAS, H2 2018 191

Melanoma - Pipeline by AIMM Therapeutics BV, H2 2018 192

Melanoma - Pipeline by AiVita Biomedical Inc, H2 2018 192

Melanoma - Pipeline by Alkermes Plc, H2 2018 193

Melanoma - Pipeline by Allergy Therapeutics Plc, H2 2018 193

Melanoma - Pipeline by Alligator Bioscience AB, H2 2018 194

Melanoma - Pipeline by Altor BioScience Corp, H2 2018 194

Melanoma - Pipeline by Amgen Inc, H2 2018 195

Melanoma - Pipeline by Angimmune LLC, H2 2018 195

Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2018 196

Melanoma - Pipeline by APEIRON Biologics AG, H2 2018 196

Melanoma - Pipeline by Apexigen Inc, H2 2018 196

Melanoma - Pipeline by Aphios Corp, H2 2018 197

Melanoma - Pipeline by Aposense Ltd, H2 2018 197

Melanoma - Pipeline by Aprea AB, H2 2018 198

Melanoma - Pipeline by Aptose Biosciences Inc, H2 2018 198

Melanoma - Pipeline by Arcus Biosciences Inc, H2 2018 199

Melanoma - Pipeline by ArQule Inc, H2 2018 199

Melanoma - Pipeline by Array BioPharma Inc, H2 2018 200

Melanoma - Pipeline by Asana BioSciences LLC, H2 2018 200

Melanoma - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018 201

Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2018 201

Melanoma - Pipeline by Atreca Inc, H2 2018 201

Melanoma - Pipeline by aTyr Pharma Inc, H2 2018 202

Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202

Melanoma - Pipeline by Autolus Therapeutics Plc, H2 2018 203

Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203

Melanoma - Pipeline by Batu Biologics Inc, H2 2018 204

Melanoma - Pipeline by Bayer AG, H2 2018 204

Melanoma - Pipeline by BeiGene Ltd, H2 2018 205

Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018 205

Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2018 206

Melanoma - Pipeline by BerGenBio ASA, H2 2018 206

List of Figures

List of Figures

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 86

Number of ...

List of Figures

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 86

Number of Products under Development by Universities/Institutes, H2 2018 107

Number of Products by Top 10 Targets, H2 2018 151

Number of Products by Stage and Top 10 Targets, H2 2018 151

Number of Products by Top 10 Mechanism of Actions, H2 2018 166

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 166

Number of Products by Routes of Administration, H2 2018 181

Number of Products by Stage and Routes of Administration, H2 2018 181

Number of Products by Top 10 Molecule Types, H2 2018 183

Number of Products by Stage and Top 10 Molecule Types, H2 2018 183

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports